{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:39Z","timestamp":1785132099156,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 Diabetes (T2D) is a chronic condition requiring lifelong personalized management to prevent disease progression and complications. Mobile health applications like dibi can substantially support patients in daily disease management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study analyzes user demographics, self-reported treatment characteristics, and early feature use among users of the dibi digital diabetes companion app to better understand app uptake and feature use, advance personalized care and facilitate predictive healthcare strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Of 5,744 dibi users, 2,422 (42.2%) provided consent and completed registration (date: 15.12.24). Users were included if they had active consent and were aged \u226518 years, resulting in 2,262 users for the main analysis. Users with missing or invalid entries were excluded from respective parameter-specific analysis. Among all included users, 1,253 (55.3%) defined at least one medication plan with overall 1,039 unique medications, and 514 (22.7%) users utilized the adherence feature at least once to track medication intake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the included users, 89.4% were patients with T2D, mostly male (57.5%), aged 56\u201365 years (33.5%) and recently diagnosed (0\u20131 year since self-reported diagnosis). Female T2D users appeared to be distributed toward younger age groups than male users and more often chose lifestyle changes only during onboarding. Most T2D users (36.9%) reported either treatment with oral antidiabetics (OAD) only or lifestyle modifications alone (17.1%). Of the T2D patients who used medication plans, the majority (57.0%) reported using only OADs, while 7.2% reported only non-diabetes medications. More escalated treatment regimens were observed with longer disease duration. While 87.5% confirmed medication intake at least once, 29.6% used the adherence feature only once.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis demonstrates that the dibi app reached a predominantly T2D user population in Germany. It provides insights into treatment patterns and patient reported lifestyle changes. The dibi cohort reflects trends seen in other studies, representing real-world disease management. These findings indicate that inclusion of medical questionnaires, and clinical metrics, such as HbA1c, will deepen our understanding of the disease and enable treatment-lifestyle correlations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fdgth.2026.1824377","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:21Z","timestamp":1785130821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["User demographics and real-world use of the digital diabetes companion app dibi: a retrospective analysis"],"prefix":"10.3389","volume":"8","author":[{"given":"Patrizia","family":"Brunner","sequence":"first","affiliation":[{"name":"Temedica GmbH","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffeni","family":"Papukchieva","sequence":"additional","affiliation":[{"name":"Temedica GmbH","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Temedica GmbH","place":["Munich, Germany"]},{"name":"Else Kroener Fresenius Center for Digital Health (EKFZ), Technical University Dresden","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Steinmetz-Sp\u00e4h","sequence":"additional","affiliation":[{"name":"Temedica GmbH","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hammer","sequence":"additional","affiliation":[{"name":"Novo Nordisk Pharma GmbH","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kienh\u00f6fer","sequence":"additional","affiliation":[{"name":"Novo Nordisk Pharma GmbH","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ebert","sequence":"additional","affiliation":[{"name":"Medical Department III \u2013 Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center","place":["Leipzig, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lautenbach","sequence":"additional","affiliation":[{"name":"Ambulanzzentrum des UKE GmbH, Department of Endocrinology and Diabetology, University Obesity Centre, University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1055\/a-2166-6755","article-title":"Therapy of type 2 diabetes","volume":"132","author":"Landgraf","year":"2024","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100459","DOI":"10.1016\/j.obmed.2022.100459","article-title":"Type 2 diabetes mellitus, its impact on quality of life and how the disease can be managed-a review","volume":"35","author":"Garg","year":"2022","journal-title":"Obes Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e51791","DOI":"10.7759\/cureus.51791","article-title":"Effect of Mobile apps on medication adherence of type 2 diabetes Mellitus: a systematic review of recent studies","volume":"16","author":"Hakami","year":"2024","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e23477","DOI":"10.2196\/23477","article-title":"Effectiveness of disease-specific mHealth apps in patients with diabetes Mellitus: scoping review","volume":"9","author":"Eberle","year":"2021","journal-title":"JMIR MHealth UHealth"},{"key":"B7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/19322968211060060","article-title":"Mobile app interventions to improve medication adherence among type 2 diabetes Mellitus patients: a systematic review of clinical trials","volume":"17","author":"Shrivastava","year":"2023","journal-title":"J Diabetes Sci Technol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00103-019-03068-9","article-title":"Pr\u00e4valenz und inzidenz des dokumentierten diabetes mellitus \u2013 referenzauswertung f\u00fcr die diabetes-surveillance auf basis von daten aller gesetzlich krankenversicherten","volume":"63","author":"Schmidt","year":"2020","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s00125-024-06113-8","article-title":"Incidence trend of type 2 diabetes from 2012 to 2021 in Germany: an analysis of health claims data of 11 million statutorily insured people","volume":"67","author":"Lehner","year":"2024","journal-title":"Diabetologia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/dme.14100","article-title":"Age at diagnosis of type 2 diabetes in Germany: a nationwide analysis based on claims data from 69 million people","volume":"37","author":"Jacobs","year":"2020","journal-title":"Diabet Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2055207619882181","DOI":"10.1177\/2055207619882181","article-title":"Use of mobile health applications for health-promoting behavior among individuals with chronic medical conditions","volume":"5","author":"Mahmood","year":"2019","journal-title":"Digit Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/01972243.2018.1438550","article-title":"Differences in mobile health app use: a source of new digital inequalities?","volume":"34","author":"Bol","year":"2018","journal-title":"Inf Soc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e18080","DOI":"10.2196\/18080","article-title":"Intention to use medical apps among older adults in The Netherlands: cross-sectional study","volume":"22","author":"Askari","year":"2020","journal-title":"J Med Internet Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e054561","DOI":"10.1136\/bmjopen-2021-054561","article-title":"Willingness, perceived barriers and motivators in adopting mobile applications for health-related interventions among older adults: a scoping review","volume":"12","author":"Ahmad","year":"2022","journal-title":"BMJ Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2055207620905422","DOI":"10.1177\/2055207620905422","article-title":"Barriers to older adults\u2019 uptake of mobile-based mental health interventions","volume":"6","author":"Pywell","year":"2020","journal-title":"Digit Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/archinternmed.2010.334","article-title":"Long term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes: four year results of the Look AHEAD trial","volume":"170","year":"2010","journal-title":"Arch Intern Med"},{"key":"B18","unstructured":"National Diabetes Surveillance Report 2019."},{"key":"B19","doi-asserted-by":"publisher","first-page":"102782","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"eClinicalMed"},{"key":"B20","year":"2023"},{"key":"B21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/s12913-019-4384-7","article-title":"Patients\u2019 perspective on self-management: type 2 diabetes in daily life","volume":"19","author":"Van Smoorenburg","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/DMSO.S214288","article-title":"Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage","volume":"12","author":"Wilke","year":"2019","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1111\/dom.15931","article-title":"Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: a claims data study","volume":"26","author":"Hennies","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e3444","DOI":"10.1002\/dmrr.3444","article-title":"A systematic review of adherence to physical activity interventions in individuals with type 2 diabetes","volume":"37","author":"MacDonald","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.3390\/nu12113516","article-title":"Low reported adherence to the 2019 American diabetes association nutrition recommendations among patients with type 2 diabetes Mellitus, indicating the need for improved nutrition education and diet care","volume":"12","author":"Katsaridis","year":"2020","journal-title":"Nutrients"},{"key":"B27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00592-020-01628-z","article-title":"The association of the level of self-care on adherence to treatment in patients diagnosed with type 2 diabetes","volume":"58","author":"Krzemi\u0144ska","year":"2021","journal-title":"Acta Diabetol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/PPA.S187080","article-title":"Associations of different adherences in patients with type 2 diabetes mellitus","volume":"13","author":"Klinovszky","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e11491","DOI":"10.7717\/peerj.11491","article-title":"Using a mobile health app to improve patients\u2019 adherence to hypertension treatment: a non-randomized clinical trial","volume":"9","author":"Volpi","year":"2021","journal-title":"PeerJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e12505","DOI":"10.2196\/12505","article-title":"Mobile apps for increasing treatment adherence: systematic review","volume":"21","author":"P\u00e9rez-Jover","year":"2019","journal-title":"J Med Internet Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e032045","DOI":"10.1136\/bmjopen-2019-032045","article-title":"Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis","volume":"10","author":"Armitage","year":"2020","journal-title":"BMJ Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e24190","DOI":"10.2196\/24190","article-title":"Mobile apps to improve medication adherence in cardiovascular disease: systematic review and meta-analysis","volume":"23","author":"Al-Arkee","year":"2021","journal-title":"J Med Internet Res"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1824377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:22Z","timestamp":1785130822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1824377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":32,"alternative-id":["10.3389\/fdgth.2026.1824377"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2026.1824377","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1824377"}}